SCHEMBL1794286

SCHEMBL1794286

CCCN(CCC)C1CCC(NCc2ccc(C(=O)N(Cc3ncc[nH]3)Cc3ncc[nH]3)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 4/20 0.58
CTSD P07339 1/20 0.43
FASN P49327 1/20 0.41
OPRD1 P41143 3/20 0.37
OPRM1 P35372 2/20 0.37
OPRK1 P41145 1/20 0.37
HDAC1 Q13547 5/20 0.37
HDAC6 Q9UBN7 4/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HDAC3 O15379 1/20 0.34
HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1794548 1.00 CXCR4 (0.58) CXCR4CTSDFASNOPRD1OPRM1
SCHEMBL1795707 1.00 CXCR4 (0.58) CXCR4CTSDFASNOPRD1OPRM1
SCHEMBL1793677 0.96 CXCR4 (0.55) CXCR4CTSDFASNOPRD1OPRM1
SCHEMBL1793675 0.96 CXCR4 (0.55) CXCR4CTSDFASNOPRD1OPRM1
SCHEMBL1794862 0.96 CXCR4 (0.54) CXCR4CTSDFASNOPRD1OPRM1
SCHEMBL1796136 0.94 CXCR4 (0.54) CXCR4CTSDFASNOPRD1OPRM1
SCHEMBL1796135 0.94 CXCR4 (0.54) CXCR4CTSDFASNOPRD1OPRM1
SCHEMBL2691922 0.93 CXCR4 (0.50) CXCR4CTSDFASNOPRD1OPRM1
SCHEMBL2691919 0.93 CXCR4 (0.50) CXCR4CTSDFASNOPRD1OPRM1
SCHEMBL1792883 0.93 CXCR4 (0.53) CXCR4CTSDFASNOPRD1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2011-06-16 US claimed
US-20080009495-A1 Compound Containing Basic Group and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-10 US claimed
EP-1790639-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP claimed
US-8822459-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-09-02 US disclosed
EP-1790639-B1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2014-03-26 EP disclosed
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2011-06-16 US disclosed
US-7951816-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2011-05-31 US disclosed
US-20080009495-A1 Compound Containing Basic Group and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-10 US disclosed
EP-1790639-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF CXCR4, CCR5, CXCL12 CXCR4 1/4885CTSD 3749/4885FASN 1789/4885
US-20080009495-A1 Compound Containing Basic Group and Use Thereof CXCR4, CCR5, CXCR3 CXCR4 1/4885CTSD 3690/4885FASN 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.